Free Trial

Atrinsic (PTIX) Competitors

Atrinsic logo
$3.22 +0.17 (+5.57%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$3.20 -0.03 (-0.78%)
As of 10/17/2025 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTIX vs. ALZN, SNGX, KZIA, PMCB, PLRZ, QLGN, SNOA, PBM, NLSP, and CPHI

Should you be buying Atrinsic stock or one of its competitors? The main competitors of Atrinsic include Alzamend Neuro (ALZN), Soligenix (SNGX), Novogen (KZIA), Nuvilex (PMCB), Polyrizon (PLRZ), Qualigen Therapeutics (QLGN), Sonoma Pharmaceuticals (SNOA), Psyence Biomedical (PBM), NLS Pharmaceutics (NLSP), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry.

Atrinsic vs. Its Competitors

Atrinsic (NASDAQ:PTIX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Atrinsic has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500.

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 35.0% of Atrinsic shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alzamend Neuro's return on equity of -151.24% beat Atrinsic's return on equity.

Company Net Margins Return on Equity Return on Assets
AtrinsicN/A -1,586.63% -585.65%
Alzamend Neuro N/A -151.24%-124.17%

Alzamend Neuro has a consensus price target of $42.00, suggesting a potential upside of 1,791.89%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Atrinsic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrinsic
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alzamend Neuro
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Alzamend Neuro had 4 more articles in the media than Atrinsic. MarketBeat recorded 4 mentions for Alzamend Neuro and 0 mentions for Atrinsic. Atrinsic's average media sentiment score of 0.00 beat Alzamend Neuro's score of -0.20 indicating that Atrinsic is being referred to more favorably in the media.

Company Overall Sentiment
Atrinsic Neutral
Alzamend Neuro Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrinsicN/AN/A-$5.53M-$9.44-0.34
Alzamend NeuroN/AN/A-$4.51MN/AN/A

Summary

Alzamend Neuro beats Atrinsic on 8 of the 11 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTIX vs. The Competition

MetricAtrinsicMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.80M$3.39B$6.09B$10.49B
Dividend YieldN/A2.28%5.73%4.80%
P/E Ratio-0.3422.5884.9827.13
Price / SalesN/A267.64519.68179.70
Price / CashN/A46.5937.1661.22
Price / Book1.6410.4112.236.52
Net Income-$5.53M-$52.47M$3.33B$276.93M
7 Day Performance-3.88%2.31%1.18%1.94%
1 Month Performance-15.93%11.13%6.16%2.20%
1 Year Performance-58.04%11.12%60.00%35.02%

Atrinsic Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTIX
Atrinsic
0.1772 of 5 stars
$3.22
+5.6%
N/A-57.4%$1.80MN/A-0.342Gap Down
ALZN
Alzamend Neuro
2.2406 of 5 stars
$2.24
+1.6%
$42.00
+1,778.4%
-85.0%$7.08MN/A0.004News Coverage
Analyst Forecast
Short Interest ↑
SNGX
Soligenix
2.4564 of 5 stars
$1.65
-4.4%
$6.00
+264.7%
-54.5%$7.06M$120K-0.4320Gap Down
KZIA
Novogen
3.89 of 5 stars
$6.96
+2.2%
$16.50
+137.1%
-73.4%$7.03M$1.51M0.0012Positive News
Short Interest ↓
PMCB
Nuvilex
0.0815 of 5 stars
$1.03
+2.9%
N/A-43.0%$7.00MN/A-1.914Short Interest ↑
High Trading Volume
PLRZ
Polyrizon
N/A$1.16
-1.7%
N/AN/A$6.95MN/A0.00N/APositive News
Short Interest ↓
Gap Down
QLGN
Qualigen Therapeutics
N/A$3.93
-2.1%
N/A-54.6%$6.65M$4.98M0.0050Short Interest ↑
SNOA
Sonoma Pharmaceuticals
1.0902 of 5 stars
$4.00
-1.8%
N/A+30.7%$6.61M$14.29M-1.64180News Coverage
PBM
Psyence Biomedical
0.5676 of 5 stars
$3.41
-4.2%
N/A-94.8%$6.38MN/A0.00N/AShort Interest ↑
Gap Down
NLSP
NLS Pharmaceutics
N/A$1.78
+0.6%
N/A-68.1%$6.34MN/A0.006News Coverage
Analyst Forecast
Short Interest ↑
CPHI
China Pharma
0.1517 of 5 stars
$1.88
+1.0%
N/A-92.3%$6.07M$4.40M0.00250Short Interest ↑

Related Companies and Tools


This page (NASDAQ:PTIX) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners